Additive effect of histaglobulin in chronic spontaneous urticaria
Phase 4
- Conditions
- Health Condition 1: L501- Idiopathic urticaria
- Registration Number
- CTRI/2023/08/056841
- Lead Sponsor
- Dr Mali Kalpana Ramanna
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Presence of symptoms for more than 6 weeks
Not on treatment for Chronic Spontaneous Urticaria with any antihistamines or drugs for minimum 2 weeks
Exclusion Criteria
Patients with infective foci
Patients with dental implants
Patients on steroid therapy/immunosuppressants, chronic autoimmune conditions.
Pregnant women,lactating women
Physical urticaria types such as cold-induced, pressure, heat-contact, solar, dermographic, vibratory, aquagenic, cholinergic, and drug-induced urticaria
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Change in the urticaria activity scoreTimepoint: Change in the urticaria activity score from baseline to 6 weeks
- Secondary Outcome Measures
Name Time Method umber in each group achieving complete or partial symptom control <br/ ><br>Corelation of ASST positivity with UAS <br/ ><br>Duration in days patients remains symptom free or minimum symptoms <br/ ><br>Improvement in the quality of life <br/ ><br>Number, incidence, nature of adverse event <br/ ><br>Change in the serum IgE & absolute Eosinophilic Count <br/ ><br>Timepoint: Adverse events will be recorded weekly & other parameters will be at baseline & at 6 weeks <br/ ><br>